Gufic Biosciences Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Latest quarter profit grew 70.7% YoY, showing strong momentum
- Company generates healthy free cash flow
CONS
- Though reporting repeated profits, the company pays out little dividend (1.6%)
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1881.10 | 37.31 | 451338.90 | 0.85 | 29012.30 | 1165.33 | 152998.80 | 1004.57 | 19.11 | 28.81 |
| DIVISLAB | 9570.55 | 86.86 | 254068.03 | 0.31 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4962.75 | 86.55 | 188767.06 | 0.77 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1150.00 | 25.42 | 114712.94 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1383.95 | 33.17 | 111803.57 | 0.94 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1945.50 | 96.14 | 105117.74 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| AUROPHARMA | 1686.00 | 26.13 | 97008.71 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2112.00 | 17.47 | 96574.55 | 0.85 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| DRREDDY | 1151.50 | 29.83 | 96113.39 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| MANKIND | 2305.85 | 46.63 | 95242.00 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2477.35 | 38.89 | 69916.93 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| GUFICBIO | 439.55 | 60.01 | 4407.92 | 0.02 | 22.31 | 70.72 | 260.82 | 16.58 | 12.56 | 17.87 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 215 | 202 | 195 | 203 | 204 | 208 | 205 | 224 | 237 | 231 | 252 | 261 | |
| 176 | 165 | 161 | 167 | 166 | 174 | 179 | 190 | 199 | 198 | 205 | 231 | |
| Operating Profit | 39 | 36 | 34 | 36 | 39 | 34 | 26 | 33 | 38 | 33 | 47 | 30 |
| OPM % | 18.32% | 18.07% | 17.55% | 17.64% | 18.91% | 16.32% | 12.86% | 14.88% | 15.96% | 14.25% | 18.75% | 11.34% |
| 0 | 0 | 1 | 1 | 0 | 2 | 0 | 1 | 2 | 1 | -1 | 0 | |
| Interest | 4 | 3 | 4 | 5 | 5 | 5 | 8 | 9 | 10 | 8 | 9 | 9 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 5 | 8 | 8 | 8 | 8 | 8 | 8 |
| Profit before Tax | 31 | 30 | 27 | 28 | 29 | 26 | 11 | 17 | 23 | 18 | 29 | 30 |
| Tax % | 25.01% | 24.70% | 26.07% | 25.79% | 25.61% | 26.50% | 26.69% | 24.32% | 25.58% | 29.91% | 24.35% | 25.72% |
| Net Profit | 0 | 0 | 0 | 21 | 22 | 19 | 8 | 13 | 17 | 12 | 22 | 22 |
| 2.39 | 2.23 | 2.00 | 2.08 | 2.17 | 1.93 | 0.77 | 1.30 | 1.68 | 1.24 | 2.18 | 2.22 |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|
| 807 | 820 | 944 | 981 | |
| 659 | 684 | 793 | 833 | |
| Operating Profit | 147 | 136 | 151 | 148 |
| OPM % | 18.26% | 16.60% | 16.03% | 15.05% |
| 2 | 4 | 3 | 2 | |
| Interest | 17 | 25 | 37 | 37 |
| Depreciation | 17 | 21 | 31 | 31 |
| Profit before Tax | 116 | 94 | 87 | 99 |
| Tax % | 25.53% | 26.02% | 25.81% | 26.04% |
| Net Profit | 86 | 70 | 64 | 73 |
| EPS | 8.59 | 6.95 | 6.40 | — |
| Dividend Payout % | 1.16% | 1.44% | 1.56% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
STOCK PRICE CAGR
- 10 Years:
- 27%
- 5 Years:
- 17%
- 3 Years:
- 13%
- 1 Year:
- 16%
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- 13%
- Last Year:
- 10%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 10 | 10 | 10 |
| 523 | 591 | 655 | |
| 313 | 310 | 379 | |
| Trade Payables | 166 | 159 | 199 |
| 81 | 100 | 99 | |
| Total Liabilities | 1,093 | 1,169 | 1,342 |
| 159 | 506 | 491 | |
| Capital Work in Progress | 307 | 22 | 22 |
| 2 | 2 | 2 | |
| 200 | 217 | 324 | |
| 330 | 315 | 297 | |
| Cash & Bank | 13 | 29 | 76 |
| 81 | 79 | 129 | |
| Total Assets | 1,093 | 1,169 | 1,342 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| -7 | 123 | 45 | |
| Cash from Investing | -102 | -71 | -31 |
| Cash from Financing | 82 | -37 | 32 |
| -27 | 15 | 46 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-08 - Gufic Biosciences Limited has informed the Exchange about Credit Rating
2026-09-07 - Gufic Biosciences Limited has submitted the Exchange a copy of Scrutinizers report and voting results of 42nd Annual General Meeting held on September 04, 2026
2026-09-04 - Gufic Biosciences Limited has informed the Exchange regarding Proceedings of 42nd Annual General Meeting held on September 04, 2026
2026-09-02 - Gufic Biosciences Limited has informed the Exchange about Promotion and Change in Designation of Senior Management Personnel
2026-08-21 - Gufic Biosciences Limited has informed the Exchange about Transcript
2026-08-18 - Gufic Biosciences Limited has informed the Exchange about Copy of Newspaper Advertisement regarding Special Window for Re-lodgement of Transfer and Dematerialization of Physical Shares
2026-08-17 - Gufic Biosciences Limited has informed the Exchange about Link of Recording
2026-08-15 - Gufic Biosciences Limited has informed the Exchange about Copy of Newspaper Advertisement of Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026
2026-08-14 - Gufic Biosciences Limited has submitted to the Exchange the Investor Presentation for the quarter ended June 30, 2026
News
Recent coverage and analyst commentary for GUFICBIO
Loading news…
AI Stock Analyst
Gufic Biosciences Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account